SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 ETF is experiencing intense volatility and aggressive price swings as the market reacts to speculative headlines regarding geopolitical tensions and potential protocols for shipping routes. The community is deeply polarized, with many retail traders accusing large institutions of orchestrating 'fake' rallies to trap bears and manipulate options liquidity before a long holiday weekend.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as the community celebrates the successful Artemis II launch and anticipates the company's pivotal role in lunar infrastructure. Investors are actively discussing a potential short squeeze fueled by high volume and institutional interest, while debating the impact of upcoming NASA contract awards and the broader momentum in the space sector.

Invesco QQQ Trust Series 1 - Units of beneficial interest

QQQ is experiencing heightened volatility and intense social media debate, driven by uncertainty surrounding geopolitical developments in the Middle East and the market's reaction to recent presidential commentary. The community remains deeply divided, with significant arguments playing out between bulls anticipating a classic dip-buy and bears pointing toward escalating oil prices and macroeconomic concerns as catalysts for a broader sell-off.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing extreme volatility as it undergoes S&P 500 index inclusion, driving a surge of forced institutional buying that has captured significant market attention. The community is sharply divided, with bulls pointing to the company's critical role in AI infrastructure and hyperscaler partnerships, while skeptical traders warn of unsustainable valuations and aggressive short-term price swings.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing intense volatility and heavy trading volume as markets closely track heightened geopolitical tensions in the Middle East and ongoing uncertainty surrounding the Strait of Hormuz. Community sentiment is deeply divided, with many traders actively debating whether the current price action represents a speculative bubble fueled by geopolitical headlines or a structural supply shock that could drive oil significantly higher.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending as investors react to the company's expansion into pharmaceutical manufacturing and the launch of new regulated laboratory products, fueling speculation about potential U.S. government contracts and domestic supply chain partnerships. The community remains focused on the company's improved balance sheet and its strategic pivot toward advanced materials, with active discussions on the long-term potential for a major industrial turnaround.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is facing downward pressure amid broader market uncertainty, with community sentiment divided between those aggressively accumulating the dip and others expressing frustration over technical volatility and ecosystem exploits like the recent Drift protocol incident. Investors remain focused on developer momentum and potential institutional adoption as key drivers that could pull the asset out of its current slump.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is attracting heavy investor attention ahead of its upcoming earnings report, with the community actively debating the company's shift toward a diversified consumer goods strategy and the potential for a significant rally should federal rescheduling news materialize. Despite frustrations over historical share price volatility and management's dilution strategy, bullish sentiment remains tied to improving medical cannabis fundamentals and hopes for a major short squeeze.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is currently surging following the announcement of a new volume order for 800G data center transceivers from a major hyperscale client, fueling intense discussion regarding the company's role in AI infrastructure. While the community is actively debating the stock's parabolic trajectory and potential for further momentum, many traders remain hyper-focused on its high volatility and the ongoing influence of institutional positioning.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

KELYB is seeing intense community activity driven by its extremely low float, which investors believe creates the potential for rapid volatility and short squeezes. Traders are closely monitoring upcoming investor calls and the influence of major institutional positions, with many debating whether the current price action represents a temporary pullback or a setup for further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 88.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 359,580 shares of the biotechnology co...

BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 28.5% during the 3rd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - What's Next?

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Should You Buy...

<ul class="summary-bullets"><li>Elevated oil prices and Middle East tensions are keeping traders on the edge.</li><li>Investors are eyeing PMI data and GameStop earnings as near-term catalysts for market direction.</li><li>AI stocks remain in focus amid fresh supply chain concerns and geopolitical scrutiny around chip exports.</li></ul>U.S. stock futures rose early Tuesday, attempting to build on the recovery seen in the previous market session. However, investors remain cautious amid the uncertainty in the Middle East. Traders will also be watching for cues from manufacturing data due this morning and Gamestop earnings later today.&nbsp;Crude oil prices rose on concerns that the Iran conflict could reportedly expand to U.S. allies in the Persian Gulf. This comes even as Iranian lawmakers dismissed the possibility of negotiations with the U.S. As of 4:30 a.m. ET on Tuesday, Dow and S&amp;P 500 futures rose 0.2%, and Nasdaq and Russell 2000 futures were up 0.3%.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘extremely bearish, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bearish’ amid high trading volume.&nbsp;Trending Stocks To Watch Nvidia (NVDA):&nbsp;Following the SMCI crisis, U.S. Senators are reportedly demanding a suspension of the AI bellwether’s GPU export licenses to China and Southeast Asia.&nbsp;Broadcom (AVGO):&nbsp;The chipmaker has reportedly warned that its manufacturing partner, TSMC, is nearing capacity for the year, adding to supply concerns.&nbsp;Oracle (ORCL) and Alibaba (BABA):&nbsp;Reports suggest they have launched significant “agentic AI” initiatives.&nbsp;Alibaba has unveiled a new chip design, while Oracle is said to be embedding AI agents in its cloud-based financial software.&nbsp;Amazon (AMZN):&nbsp;The company has said its Bahrain AWS region has been disrupted by drone activity in the Middle East.&nbsp;Gamestop (GME):&nbsp;The video game retailer reports earnings after the bell today. Investors will be tracking any updates on its Bitcoin treasury or an AI-driven pivot.BioCryst Pharmaceuticals (BCRX): The stock is garnering heavy retail attention following takeover speculation.Applied Optoelectronics (AAOI):&nbsp;The stock was trending on Stocktwits following confirmation of a $53 million order for its 800G data center transceivers.&nbsp;Vertiv Holdings Co. (VRT): The stock is on retail radar after it agreed to acquire Italy-based ThermoKey.&nbsp;And&nbsp;Estee Lauder&nbsp;(EL)&nbsp;is reportedly exploring a merger with Puig. Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Intuitive Machines (LUNR), Micron Technologies (MU), Fastly Inc (FSLY), and The Metals Company (TMC).&nbsp;Other Catalysts To WatchOn the economic front, investors will be tracking the S&amp;P Global Manufacturing &amp; Services PMI at 9:45 am ET. Also, watch out for commentary from&nbsp;Fed Vice Chair for Supervision&nbsp;Michael Barr‘s speech at 6:30 pm ET.&nbsp;On earnings radar, watch out for quarterly reports from&nbsp;Achieve Life Sciences Inc.(ACHV), Greenland Technologies Holding Corp (GTEC), and Huami Corp (ZEPP), before the bell. Meanwhile.&nbsp;Fortress Biotech Inc (FBIO), Durect Corp (DRRX), and Scienture Holdings Inc. (SCNX) are among other companies reporting after market close today.&nbsp; For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Rise Ahead Of PMI Data, Iran Tensions Cap Risk Appetite: Why NVDA, GME, AAOI, BCRX Are Keeping Traders Engaged Today

Data from Stocktwits indicated that retail sentiment has remained bearish on SPY and QQQ for over a week. 

Equity

Data from Stocktwits indicated that retail sentiment has remained bearish on SPY and QQQ for over a week. 


BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen brokerages that are presently covering the stock, MarketBeat...

<ul class="summary-bullets"><li>Retail traders debated the timing and pricing of the buyout, with some expecting an all-cash offer and others speculating about various takeover scenarios.</li><li>Skeptical users noted BioCryst’s history as an acquirer and argued shares would likely trade closer to $14-$15 if firm deal insights existed.</li><li>The company's growth remains anchored by Orladeyo, which generated $601 million in revenue and $214 million in non-GAAP operating profit last year.</li></ul>Shares of BioCryst Pharmaceuticals, Inc. (BCRX) jumped about 11% in after-hours trading on Monday as retail sentiment hit its strongest level of 2026 and volumes doubled, fueling speculation that a U.S. biopharma worth over $15 billion could be circling the company.<a href="https://stocktwits.com/symbol/BCRX">BCRX stock</a> ended over 1% higher at $9.8 on Monday, with shares up 23% over the past year.<h2 class="st-heading-2">Retail Investors Weigh Buyout Odds For BCRX</h2>The renewed takeover buzz followed last week's reports of a Betaville “uncooked” alert, which said that a party interested in BioCryst may be a U.S.-based biopharma firm with a market cap exceeding $15 billion.&nbsp;Among the biotech companies with a market cap between $15 billion and $20 billion are Incyte Corp., Revolution Medicines, Inc., Roivant Sciences Ltd., and Exact Sciences Corp.On Stocktwits, retail sentiment for BCRX has remained ‘extremely bullish’ over the past three months and recently climbed to its strongest level of 2026 amid nearly a 300% surge in message volumes, with investors debating whether the after-hours rally reflected positioning ahead of a potential acquisition.<figure class="image"><img src="https://news.stocktwits-cdn.com/bcrx_ss_png_4999553778.webp" alt="bcrx ss.png" width="967" height="144"><figcaption>BCRX sentiment and message volume as of March 23 | Source: Stocktwits</figcaption></figure>One trader&nbsp;<a href="https://stocktwits.com/SCCT2FL/message/648340880">said</a>, “Somebody knows something. A $10 stock doesn’t just go up 10%+ for nothing after hours.” Meanwhile, another trader&nbsp;<a href="https://stocktwits.com/Iwillbuy/message/648308700">expects</a> a buyout to be announced as soon as Wednesday, in an all-cash offer.Some observers&nbsp;<a href="https://stocktwits.com/tkr/message/648180984">suggested</a> institutional positioning at lower levels supported the takeover narrative, arguing that entry around $9.7 signaled confidence in further upside and the possibility that larger pharmaceutical companies could emerge as bidders.<figure class="image"><img src="https://news.stocktwits-cdn.com/bcrx_sentiment_png_404b898eb7.webp" alt="bcrx sentiment.png" width="973" height="447"><figcaption>BCRX sentiment as of March 23 | Source: Stocktwits</figcaption></figure>Others&nbsp;<a href="https://stocktwits.com/Money_Mane/message/648056955">framed</a> possible price scenarios depending on whether a deal materializes, estimating the shares could reach $16-$18 in a buyout case, trade toward $13-$16 with continued execution, or fall toward $7-$9 if competition increases, with further downside possible if pipeline expectations weaken.&nbsp;However, not all views supported the takeover thesis. One user&nbsp;<a href="https://stocktwits.com/doublebtx/message/648310647">noted</a> that the company’s history suggested it may prefer acting as an acquirer rather than a target, while another argued that if investors had firm takeover insight, the stock would already be trading closer to $14-$15.&nbsp;“If the BO [buyout] speculation (if that even is what is happening) goes away, this certainly could drop back,”&nbsp;<a href="https://stocktwits.com/doublebtx/message/648126797">said</a> one user. “But I would just like to point out that even at these levels, this is not even trading at 4x current revs. So it is certainly not overvalued here with or without BO rumors.”<h2 class="st-heading-2">Orladeyo Anchors Growth Outlook</h2>The takeover speculation surfaced alongside improving pipeline visibility, highlighted earlier this month at the TD Cowen 46th Annual Health Care Conference. CEO Charlie Gayer said the company generated $601 million in revenue last year from Orladeyo, its oral preventive treatment for hereditary angioedema, and $214 million in non-GAAP operating profit.“Orladeyo is still the most differentiated product on the market because it’s the only oral prophylactic on the market today,” Gayer said, adding that half of the patients starting Orladeyo are switching from injectable prophylaxis therapies.The company also highlighted Navenibart, the late-stage hereditary angioedema therapy&nbsp;acquired with Astria, as a key driver of future franchise expansion. It also noted that the composition-of-matter patent protection for Orladeyo extends to 2040.Gayer added that the broader portfolio outlook remains strong: “We’re talking about a portfolio that we see growing at mid-teens in revenue well into the 2030s.”For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

BioCryst Stock Jumps After Hours On Big Pharma Suitor Buzz — Retail Sentiment Hits 2026 Peak

Betaville’s “uncooked” alert from last week flagged potential interest in BioCryst from a U.S.-based biopharma with a market cap above $15 billion.

Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today?

Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 150,000 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 150,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the completion of the...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 150,000 shares of the company's stock in a transaction dated Monday, March 16th. The shares were sold at an...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 13.8% - Here's What Happened

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 13.8% - Should You Buy...

Top Biotech Stocks To Keep An Eye On - March 16th

Danaher, Vertex Pharmaceuticals, Moderna, BioCryst Pharmaceuticals, ImmunityBio, argenex, and Abivax are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Current Price	$9.13
Prev Close	$9.38
Open	$9.29
Dividend Yield	0.00%
50-Day Moving Average	$7.93
Beta	0.91
Avg. Volume	6.83M
PE Ratio	7.80

52-Week High	$11.31
52-Week Low	$6.00
Market Capitalization	$2.35B
EPS (Annual)	$1.21
Price to Book	-16.77
Revenue Per Employee	$2.01M

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.